Limits...
HNF1B polymorphism influences the prognosis of endometrial cancer patients: a cohort study.

Mandato VD, Farnetti E, Torricelli F, Abrate M, Casali B, Ciarlini G, Pirillo D, Gelli MC, Nicoli D, Grassi M, LA Sala GB, Palomba S - BMC Cancer (2015)

Bottom Line: At multivariate analysis, a significant (P < 0.05) effect on overall survival was detected for FIGO stage, and rs4430796 polymorphism of HNF1B gene.After grouping EC patients according to adjuvant treatment, rs4430796 polymorphism resulted significantly (P < 0.001) related to overall survival only in subjects who received radiotherapy plus chemotherapy.Finally, only a trend (P = 0.090) towards significance was observed for rs4430796 polymorphism effect on progression free survival. rs4430796 polymorphism of HNF1B gene influences independently the prognosis of EC patients with a potential effect on tumor chemo-sensitivity.

View Article: PubMed Central - PubMed

Affiliation: Unit of Obstetrics and Gynecology, IRCCS-Arcispedale Santa Maria Nuova, Reggio Emilia, Italy. dariomandato@virgilio.it.

ABSTRACT

Background: HNF1B (formerly known as TCF2) gene encodes for a transcription factor that regulates gene expression involved in normal mesodermal and endodermal developments. A close association between rs4430796 polymorphism of HNF1B gene and decreased endometrial cancer (EC) risk has been demonstrated. The aim of the current study was to test the hypothesis that rs4430796 polymorphism can influence the prognosis of EC patients.

Methods: Retrospective cohort study. Clinical and pathological data were extrapolated and genotypes were assessed on formalin-fixed and paraffin-embedded non-tumour tissues. The influence of patients' genotype on overall survival and progression free survival were our main outcome measures.

Results: A total of 191 EC patients were included in the final analysis. Overall survival differed significantly (P = 0.003) among genotypes. At multivariate analysis, a significant (P < 0.05) effect on overall survival was detected for FIGO stage, and rs4430796 polymorphism of HNF1B gene. After grouping EC patients according to adjuvant treatment, rs4430796 polymorphism resulted significantly (P < 0.001) related to overall survival only in subjects who received radiotherapy plus chemotherapy. A significant (P = 0.014) interaction between rs4430796 polymorphism and chemo-radiotherapy was also detected. Finally, only a trend (P = 0.090) towards significance was observed for rs4430796 polymorphism effect on progression free survival.

Conclusions: rs4430796 polymorphism of HNF1B gene influences independently the prognosis of EC patients with a potential effect on tumor chemo-sensitivity.

No MeSH data available.


Related in: MedlinePlus

Kaplan-Meier plot of estimate probability of overall survival comparing GG vs. AG + AA rs4430796 genotypes in EC patients classified according to adjuvant treatment. Log-rank test P < 0.0001.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC4403886&req=5

Fig2: Kaplan-Meier plot of estimate probability of overall survival comparing GG vs. AG + AA rs4430796 genotypes in EC patients classified according to adjuvant treatment. Log-rank test P < 0.0001.

Mentions: The effect of rs4430796 polymorphism on OS in EC patients according to adjuvant therapy is showed in Figure 2. No significant effect was detected in EC patients who did not receive adjuvant therapy and in those treated with radiotherapy (Figure 2). In EC patients who received radiotherapy plus chemotherapy a significant (P < 0.001) effect of rs4430796 polymorphism on OS was detected. A significant (P = 0.014) interaction between rs4430796 polymorphism and chemo-radiotherapy was also observed (Figure 2). A significantly (P < 0.001) worse OS was observed only in subjects with GG genotype who received radio-chemotherapy as adjuvant treatment (Figure 2).Figure 2


HNF1B polymorphism influences the prognosis of endometrial cancer patients: a cohort study.

Mandato VD, Farnetti E, Torricelli F, Abrate M, Casali B, Ciarlini G, Pirillo D, Gelli MC, Nicoli D, Grassi M, LA Sala GB, Palomba S - BMC Cancer (2015)

Kaplan-Meier plot of estimate probability of overall survival comparing GG vs. AG + AA rs4430796 genotypes in EC patients classified according to adjuvant treatment. Log-rank test P < 0.0001.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC4403886&req=5

Fig2: Kaplan-Meier plot of estimate probability of overall survival comparing GG vs. AG + AA rs4430796 genotypes in EC patients classified according to adjuvant treatment. Log-rank test P < 0.0001.
Mentions: The effect of rs4430796 polymorphism on OS in EC patients according to adjuvant therapy is showed in Figure 2. No significant effect was detected in EC patients who did not receive adjuvant therapy and in those treated with radiotherapy (Figure 2). In EC patients who received radiotherapy plus chemotherapy a significant (P < 0.001) effect of rs4430796 polymorphism on OS was detected. A significant (P = 0.014) interaction between rs4430796 polymorphism and chemo-radiotherapy was also observed (Figure 2). A significantly (P < 0.001) worse OS was observed only in subjects with GG genotype who received radio-chemotherapy as adjuvant treatment (Figure 2).Figure 2

Bottom Line: At multivariate analysis, a significant (P < 0.05) effect on overall survival was detected for FIGO stage, and rs4430796 polymorphism of HNF1B gene.After grouping EC patients according to adjuvant treatment, rs4430796 polymorphism resulted significantly (P < 0.001) related to overall survival only in subjects who received radiotherapy plus chemotherapy.Finally, only a trend (P = 0.090) towards significance was observed for rs4430796 polymorphism effect on progression free survival. rs4430796 polymorphism of HNF1B gene influences independently the prognosis of EC patients with a potential effect on tumor chemo-sensitivity.

View Article: PubMed Central - PubMed

Affiliation: Unit of Obstetrics and Gynecology, IRCCS-Arcispedale Santa Maria Nuova, Reggio Emilia, Italy. dariomandato@virgilio.it.

ABSTRACT

Background: HNF1B (formerly known as TCF2) gene encodes for a transcription factor that regulates gene expression involved in normal mesodermal and endodermal developments. A close association between rs4430796 polymorphism of HNF1B gene and decreased endometrial cancer (EC) risk has been demonstrated. The aim of the current study was to test the hypothesis that rs4430796 polymorphism can influence the prognosis of EC patients.

Methods: Retrospective cohort study. Clinical and pathological data were extrapolated and genotypes were assessed on formalin-fixed and paraffin-embedded non-tumour tissues. The influence of patients' genotype on overall survival and progression free survival were our main outcome measures.

Results: A total of 191 EC patients were included in the final analysis. Overall survival differed significantly (P = 0.003) among genotypes. At multivariate analysis, a significant (P < 0.05) effect on overall survival was detected for FIGO stage, and rs4430796 polymorphism of HNF1B gene. After grouping EC patients according to adjuvant treatment, rs4430796 polymorphism resulted significantly (P < 0.001) related to overall survival only in subjects who received radiotherapy plus chemotherapy. A significant (P = 0.014) interaction between rs4430796 polymorphism and chemo-radiotherapy was also detected. Finally, only a trend (P = 0.090) towards significance was observed for rs4430796 polymorphism effect on progression free survival.

Conclusions: rs4430796 polymorphism of HNF1B gene influences independently the prognosis of EC patients with a potential effect on tumor chemo-sensitivity.

No MeSH data available.


Related in: MedlinePlus